Literature DB >> 19283840

Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis.

Scott D Sagel1, Marci K Sontag, Frank J Accurso.   

Abstract

Antimicrobial proteins are important in lung defense and are potential therapeutic agents in chronic airways infection such as seen in cystic fibrosis (CF). In preparation for future clinical studies, we sought (1) to determine levels of three antimicrobial proteins [lactoferrin, lysozyme, and secretory leukoprotease inhibitor (SLPI)] in the CF airway and (2) to examine the relationships between these antimicrobial proteins and airway inflammation and infection. We examined bronchoalveolar lavage fluid (BALF) from 45 individuals with CF and 23 disease control individuals. Airway inflammation was measured through BALF neutrophil counts and neutrophil elastase activity. Infection was assessed through quantitative counts of CF-related bacterial pathogens. BALF lysozyme activity and lactoferrin levels were elevated in individuals with CF compared to controls whereas SLPI levels were not different between the groups. Among the CF subjects, lysozyme activity and lactoferrin increased with age while SLPI decreased with age. Lysozyme activity and lactoferrin concentrations correlated positively with neutrophil counts but not with bacterial colony counts. SLPI levels were inversely related to both neutrophil counts and bacterial colony counts. This study provides information concerning the levels of antimicrobial proteins present in the CF airway that are relevant to future clinical trials of these compounds and demonstrates clear relationships between antimicrobial protein-specific levels and airway inflammation and infection. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283840     DOI: 10.1002/ppul.21028

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  23 in total

1.  SPLUNC1 promotes lung innate defense against Mycoplasma pneumoniae infection in mice.

Authors:  Fabienne Gally; Y Peter Di; Sean K Smith; Maisha N Minor; Yang Liu; Donna L Bratton; S Courtney Frasch; Nicole M Michels; Stephanie R Case; Hong Wei Chu
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Innate immunity in the respiratory epithelium.

Authors:  Dane Parker; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2011-02-17       Impact factor: 6.914

3.  MUC5B expression and location in surfactant protein C mutations in children.

Authors:  Deborah R Liptzin; Alan M Watson; Elissa Murphy; Miranda E Kroehl; Megan K Dishop; Csaba Galambos; Christopher M Evans; Marvin I Schwarz; Robin R Deterding; David A Schwartz
Journal:  Pediatr Pulmonol       Date:  2015-04-07

4.  Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.

Authors:  Silvia M Caceres; Kenneth C Malcolm; Jennifer L Taylor-Cousar; David P Nichols; Milene T Saavedra; Donna L Bratton; Samuel M Moskowitz; Jane L Burns; Jerry A Nick
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.

Authors:  Rafael Marino; Thusanth Thuraisingam; Pierre Camateros; Cynthia Kanagaratham; Yong Zhong Xu; Jennifer Henri; Jingxuan Yang; Guoan He; Aihao Ding; Danuta Radzioch
Journal:  J Immunol       Date:  2011-02-18       Impact factor: 5.422

Review 6.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Bridget Stuart; Jenny H Lin; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2010-06-16       Impact factor: 2.726

7.  Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection.

Authors:  Benjamin J Staudinger; Jocelyn Fraga Muller; Skarphéðinn Halldórsson; Blaise Boles; Angus Angermeyer; Dao Nguyen; Henry Rosen; Olafur Baldursson; Magnús Gottfreðsson; Guðmundur Hrafn Guðmundsson; Pradeep K Singh
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 8.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

Review 9.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

10.  Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection.

Authors:  Charlotte C Teneback; Thomas C Scanlon; Matthew J Wargo; Jenna L Bement; Karl E Griswold; Laurie W Leclair
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.